Breast cancer researcher to receive memorial lecture award

• HemOnc Today

Researchers to be honored at San Antonio Breast Cancer Symposium

• HemOnc Today

The 2019 San Antonio Breast Cancer Symposium: What to Expect

• Cancer Therapy Advisor

Breast Cancer Meeting ‘Is Going to Be Spectacular’

• Medscape

Emerging Alternatives in the Third-Line Setting for Metastatic HER2-Positive Breast Cancer

• The Asco Post

FDA Pipeline: Treatments for HER2-Positive Breast Cancer, AML; Breakthrough Device for Prostate Cancer; Statement on Safety Information for Breast Implants

• The Asco Post

San Antonio medical school gets millions to research breast cancer

• San Antonio Express-News

Adjuvant T-DM1 Approaches EU Approval for HER2+ Early Breast Cancer

• OncLive

MacroGenics’ Metastatic Breast Cancer Drug Shows Survival Benefits in Phase III Trial

• PharmaLive

Tucatinib Shows Positive Results in Pivotal Trial in Locally Advanced HER2+ Breast Cancer

• Onco’Zine

Novel Anti-HER2 Agents Look to Change Practice at SABCS

• MedPage Today

Five Key Studies at the San Antonio Breast Cancer Symposium 2019 Conference

• Pharmacy Times

Retrospective review: Proton therapy well tolerated in patients undergoing breast conserving surgery

• The Medical News

Press Program Coverage

December 11, 2019

New HER2 Antibody-drug Conjugate Yielded Promising Clinical Responses in Breast Cancer Patients Pretreated with T-DM1

• The Associated Press, featured in approximately 300 outlets, including:

• The New York Times
• Los Angeles Times
• US News & World Report
• ABC News

• CBS Evening News, aired approximately 637 times in both TV and radio newscasts in major media markets across the U.S, including:
• oNew York
• oBuffalo
• oOrlando
• oPhoenix
• oBaltimore
• oDenver
• oPittsburgh
• oDallas
• oCharlottesville
• oCleveland
• oBoston
• oNew Orleans
• oPhiladelphia
• oLos Angeles
• oMiami
• Rueters, featured in approximately 12 outlets, including:
• oLondon Free Press
• oPhysician’s Weekly
• oDaily Mail
• oFinancial Post
• Forbes
• The ASCO Post
• The ASCO Post, Video
• Drugs.com
• Vantage
• Targeted Oncology
• MedPage Today
• MedPage Today2
• OncLive
• Medscape
• Medscape2
• DocWire News
• Herald Globe
• American Journal of Managed Care
• MDEdge
• Onco’Zine
• Onco’Zine2
• ecancer
• ecancer2
• Cancer Network
• Healio

Advisory: Adding Tucatinib to Trastuzumab and Chemotherapy Improves Survival for Patients with Metastatic HER2-Positive Breast Cancer

• MedPage Today
• The ASCO Post
• FierceBiotech
• Medscape
• HemOnc Today
• Cancer Therapy Advisor
• Pharmacy Times

Addition of S-1 to Post-operative Endocrine Therapy Improves Outcomes for Patients with Hormone Receptor-positive, HER2-negative Breast Cancer

• Cancer Network
• The ASCO Post
• OncLive
• Pharmacy Times
• OncoZine
• MDEdge
• ecancer
• ecancer2
• Healio

Updated APHINITY Trial Data Show Addition of Pertuzumab to Trastuzumab Plus Chemotherapy Continues to Yield Clinical Benefit in Patients With Operable HER2-positive Early Breast Cancer

• Medscape
• Cancer Network
• Cancer Therapy Advisor
• MDedge
• MedPage Today
• The ASCO Post
• ecancer
• ecancer2

Combining Endocrine Therapy with a CDK4/6 Inhibitor Results In Similar Response Rates to Chemotherapy for High-Risk Luminal B Breast Cancer

• OncLive
• The ASCO Post
• MedPage Today
• Medscape
• MDEdge
• Onco’Zine
• Medical Xpress
• Onco’Zine

December 12, 2019Neoadjuvant Treatment with Pembrolizumab Improves Pathologic Complete Response Rates for Patients with Triple-Negative Breast Cancer with Lymph Node Involvement

• OncLive
• OncLive2
• Cure Today
• The ASCO Post
• MDEdge
• Medscape
• ecancer
• ecancer2
• GenomeWeb
• Healio

Combining Atezolizumab with Neoadjuvant Chemotherapy Does Not Improve Pathologic Complete Response Rates for Patients with Triple-Negative Breast Cancer

• MedPage Today
• The ASCO Post
• OncLive
• MDEdge
• ecancer
• ecancer2
• Breastcancer.org
• Healio

Breast Cancer Preventive Effects of Anastrozole Persist Long After Stopping Treatment

• BBC News
• The Mirror
• OncLive
• Cancer Network
• Medscape
• Medscape
• The ASCO Post
• MedPage Today
• ecancer
• ecancer2
• Medical Xpress
• Healio
• HealthDay, featured in approximately 15 outlets, including:
• oDoctors Lounge
• oPhysician Briefings
• oPhysician’s Weekly
• oDrugs.com
• oBreitbart
• oHealthDay Consumer

Partial Breast Irradiation May be as Effective as Whole Breast Irradiation in Preventing Recurrence in Patients with Early Breast Cancer

• Daily Mail
• London Daily Mail
• MDedge
• The ASCO Post
• The ASCO Post Video
• Medscape
• OncLive
• HealthDay, featured in approximately 13 outlets, including:
• oThe New York Post
• oDrugs.com
• oDoctors Lounge
• oUS News Health
• oMedical Xpress
• oUC San Diego Health
• ecancer
• ecancer2
• Healio

MINDACT Trial Data Reveal Certain Women With Luminal Breast Cancer May Be Undertreated With Tamoxifen Alone (The decreased media coverage is due to Dr. Cardoso as a no-show for all on-site interviews.)

• OncLive
• American Journal of Managed Care

December 13, 2019

Long-term Follow-up Shows Estrogen Alone and Estrogen Plus Progestin Have Opposite Effects on Breast Cancer Incidence in Postmenopausal Women

• The Associated Press, featured in approximately 177 outlets, including:
• oThe Washington Post
• oNBC News
• oABC News
• The ASCO Post
• The ASCO Post Video
• Daily Mail
• Medscape
• Cancer Therapy Advisor
• MedPage Today
• Pharmacy Times
• HealthDay, featured in approximately 7 outlets, including:
• oUS News and World Report
• oDoctors Lounge
• oDrugs.com
• ecancer
• ecancer2
• Healio
• OncLive

Residual Cancer Burden Can Predict Outcomes for Patients With Any Breast Cancer Type

• The ASCO Post
• MedPage Today
• Cancer Therapy Advisor
• OncLive
• MDEdge
• ecancer
• ecancer2
• Healio

Circulating Tumor DNA May Help Predict Recurrence in Patients with Early Triple-Negative Breast Cancer

• The ASCO Post
• The ASCO Post Video
• OncLive
• American Journal of Managed Care
• Medscape
• MedPage Today
• ecancer
• ecancer2
• GenomeWeb
• Healio

Oral Paclitaxel Yielded Better Outcomes Than Intravenous Paclitaxel for Metastatic Breast Cancer Patients in Phase III Trial

• The ASCO Post
• The ASCO Post Video
• MedPage Today
• Medscape
• OncLive
• Pharmacy Times
• ecancer
• ecancer2
• DocWire News
• Healio

Additional SABCS Coverage

Everyday Health

• San Antonio Breast Cancer Symposium: Immunotherapy May Help Some Women With Triple Negative Breast Cancer, and More From Day 2 of the Conference

Daily Mail

• Smart blood test can identify whether women with aggressive breast cancer will respond to precision drugs, study finds

OncLive

• Margetuximab Update Elucidates Clinical Benefit in HER2+ Metastatic Breast Cancer
• Palbociclib Real-World Results Indicate OS Benefit in Frontline HR+/HER2- Breast Cancer
• Adjuvant T-DM1 for Early HER2+ Breast Cancer Demonstrates Low Recurrence Rate
• Survival Benefit Hinted at With Durvalumab Maintenance in TNBC
• Subcutaneous Fixed-Dose Pertuzumab/Trastuzumab Proves Noninferiority Versus IV Drugs
• Further Data Demonstrate Equivalence for Subcutaneous, IV Formulations of Trastuzumab in HER2+ Breast Cancer
• Atezolizumab Plus Cobimetinib/Vemurafenib Meets PFS Endpoint in Frontline BRAF V600+ Advanced Melanoma
• Dr. Pinilla Alba on Safety Findings of the PARTNER Trial in Breast Cancer
• Analysis Unable to Achieve Concordance Among PD-L1 Assays in TNBC
• Neoadjuvant Olaparib Combo Safe in Breast Cancer
• Adjuvant T-DM1 Benefit in HER2+ Breast Cancer Observed Across Key Subgroups
• Dr. Rugo on Updated Data From the SOPHIA Trial in HER2+ Metastatic Breast Cancer
• Dr. Hurvitz on Using ADCs in HER2+ Breast Cancer
• Dr. Murthy on HER2CLIMB Trial Results in HER2+ Breast Cancer
• Dr. Conte on the OlympiAD Trial in BRCA-Mutated HER2-Negative Breast Cancer
• Dr. Lin on Impact of Neratinib on CNS Metastases in HER2+ Breast Cancer
• Neoadjuvant Durvalumab Regimen Shows Promise in TNBC
• Extended Follow-Up Shows Continued Olaparib Benefit in BRCA+ MBC
• Dr. Hart on Antibody-Drug Conjugates in HER2+ Breast Cancer
• Taxane Choice With Pertuzumab/Trastuzumab in HER2+ MBC Does Not Affect Outcome
• FDA Approval Sought for Margetuximab in HER2+ Metastatic Breast Cancer

Pharmacy Times

• Understanding Different Mechanisms of Resistance to Abemaciclib, Palbociclib Presents New Therapeutic Strategies
• Study: CDK4/6 Mechanisms of Resistance Differ By Type of Inhibitor Used
• Specific Education, Training Needs Required for Appropriate Therapeutic Decision-Making for Women with HR-Positive, HER2-Negative Breast Cancer
• Endocrine Therapy for HER-Positive, HER2-Negative Breast Cancer is Improving, but More Research Needed
• Signaling Pathway Found to Influence Resistance to Fulvestrant, Palbociclib in Patients with Breast Cancer
• HER2+ Treatment Research is Thriving
• Efficacy of Palbociclib Plus Letrozole in Treatment of HER-Positive, HER2-Negative Metastatic Breast Cancer
• Addition of Abemaciclib to Aromatase Inhibitors Associated with Durable Tumor Responses
• Using the Cancer Immunity Cycle to Improve Checkpoint Blockade Responses
• When to Discuss Clinical Trials with Patients
• The Emerging Role of Immunotherapy in Breast Cancer
• Characterizing Immune-Related Side Effects in Breast Cancer Treatment
• Roche says subcutaneous dosing of Perjeta, Herceptin fixed-dose combination comparable to intravenous formulations

Cancer Therapy Advisor

• Endocrine Therapy With Palbociclib: No PFS Advantage in Metastatic Breast Cancer
• CD16A-F Carriers Appear to Benefit Most From Margetuximab and Chemo
• Breast Cancer Risk Identified for Predisposition Genes in General Population
• Prediction Models May Help Forecast Response, Adverse Events With CDKI Therapy
• Tumor Biopsy Does Not Improve Predictive Value of Trimodality Imaging
• Study Finds Many Breast Cancer Drugs Lack Substantial Clinical Benefit
• Adjuvant Paclitaxel and Trastuzumab Offer Same Survival Outcomes in HER2-Positive Early Breast Cancer
• Subcutaneous Pertuzumab and Trastuzumab Offers Convenience to Patients With HER2-Positive Breast Cancer
• Maintenance Durvalumab Shows Activity in Certain Breast Cancer Subgroups

The Medical News

• Radiation therapy alone found to be cost-effective for treatment of DCIS
• Treatment combination improves survival in advanced HER2-positive breast cancer patients
• 10-year results from clinical trial of extended letrozole therapy for women with HR+ breast cancer

Medscape

• Measuring Therapeutic Intervention Impact, Receptiveness for Patients With Breast Cancer
• The Value of Genomic Profiling for Women with Breast Cancer
• Dr. Rugo on Updated SOPHIA Data in HER2+ Metastatic Breast Cancer

MedPage Today

• T-DM1 Falls Short as Less-Toxic Option for Early Breast Cancer
• Anti-CDK4/6 Fails to Top Chemo in HR-Positive MBC
• Edging Closer to OS Benefit With Novel Anti-HER2 Drug
• SABCS Expert Roundtable: Episode 1
• SABCS: Changing Practice in the First Two Hours
• Updated APHINITY Supports Benefit of Anti-HER2 Combo

The Cancer Letter

• ‘Call me Doctor’ How women in oncology are fighting for cultural change

San Antonio Express-News

• ‘I belong here’: Advocate works to raise profile of black women with breast cancer
• MRI scans are better than mammograms for certain types of breast cancer screenings, researchers find

The ASCO Post

• SABCS 2019: [Fam-] Trastuzumab Deruxtecan in Patients With Pretreated HER2-Positive Metastatic Breast Cancer
• SABCS 2019: Adding Tucatinib to Capecitabine/Trastuzumab Improved Survival for Patients With Advanced HER2-Positive Breast Cancer
• Subcutaneous Fixed-Dose Pertuzumab/Trastuzumab Proves Noninferiority Versus IV Drugs
• Terry P. Mamounas, MD, MPH, on Extending Letrozole Treatment in Hormone Receptor–Positive Breast Cancer
• Hongchao Pan, PhD, on an Update on 5 Years of Endocrine Therapy for Early Breast Cancer
• Nadine M. Tung, MD, on HER2-Negative Breast Cancer: INFORM Trial of Cisplatin vs Doxorubicin/Cyclophosphamide
• Ivana Sestak, PhD, on Clinical Treatment Score From TAILORx: Predicting Distant Breast Cancer Recurrence
• Marie-Jeanne T.F.D. Vrancken Peeters, MD, PhD, on Omitting Breast Surgery: Results of the MICRA Trial
• Ariella B. Hanker, PhD, on Therapeutic Implications of HER2 and HER3 Mutations in Breast Cancer
• Joerg Heil, MD, PhD, on Image-Guided Vacuum-Assisted Breast Biopsy
• Hope S. Rugo, MD, on HER2-Positive Metastatic Breast Cancer: SOPHIA Trial of Chemotherapy Plus Margetuximab or Trastuzumab
• Javier Cortes, MD, PhD, on Triple-Negative Breast Cancer: Results From the KEYNOTE-119 Trial of Pembrolizumab vs Chemotherapy
• Joseph Sparano, MD: The William L. McGuire Memorial Lecture
• Belinda Kingston, MB ChB, on the Genomic Landscape of Breast Cancer Based on ctDNA Analysis
• Tari A. King, MD, on Molecular Differences Between Primary and Metastatic Breast Tumors
• Rashmi K. Murthy, MD, on HER2-Positive Metastatic Breast Cancer: HER2CLIMB Trial of Tucatinib, Capecitabine, and Trastuzumab
• Nicholas C. Turner, MD, PhD, on ctDNA Testing to Direct Targeted Therapies in Advanced Breast Cancer
• Priyanka Sharma, MD, on Postoperative Treatment of Primary Breast Cancer: POTENT Trial
• Ralph R. Weichselbaum, MD, on Oligometastatic Cancer: The Role of Radioimmunotherapy
• Miguel Martín, MD, PhD, on Metastatic Breast Cancer: PEARL Trial on Palbociclib Plus Endocrine Therapy vs Capecitabine
• Sara M. Tolaney, MD, MPH, on HER2-Positive Breast Cancer: ATEMPT Trial on T-DM1 vs Paclitaxel Plus Trastuzumab

MDEdge

• PEARL lacks luster in metastatic breast cancer progressing on AIs
• TNBC: Weekly nab-paclitaxel delivers, denosumab disappoints
• TNBC: Adding capecitabine boosts disease-free survival in prospective trial
• Capecitabine extends survival in triple-negative breast cancer
• Tucatinib called game-changer in HER2-positive metastatic breast cancer
• Chemotherapy better for metastatic breast cancer maintenance than durvalumab
• Sensitivity of ctDNA equivalent to that of tumor tissue sequencing

Onco’Zine

• SABCS 2019: Women at Elevated Risk of Breast Cancer May Benefit From Anti-inflammatory Drugs

Cancer Network

• Nadine M. Tung, MD, Discusses Germline Testing in Patients with Breast Cancer
• Corey Speers, MD, PhD, Discusses Personalized Radiation Treatment and Genomic Signatures

ecancer

• The emerging role of immunotherapy for the treatment of early and advanced breast cancer
• Adjuvant trastuzumab emtansine vs paclitaxel and trastuzumab for HER2-positive breast cancer
• Breast cancer screening and treatment in Brazil
• Cisplatin versus doxorubicin/cyclophosphamide as neoadjuvant treatment in germline BRCA carriers with HER2-negative BC
• Implementation of genetic testing in breast cancer patients
• HER2CLIMB: Investigating tucatinib with capecitabine and trastuzumab in HER2-positive metastatic breast cancer
• Exploring adjuvant endocrine therapy use with letrozole in postmenopausal women with hormone receptor-positive breast cancer
• Imaging women who are high risk for breast cancer
• The PEARL study: Palbociclib and endocrine therapy vs capecitabine in HR /HER2- metastatic breast cancer
• SABCS 2019 roundup and highlights
• The importance of central pathology pCR review in an international multicenter neoadjuvant study in HER2 positive early BC
• The challenges of treating breast cancer in Brazil
• Selective oestrogen receptor degraders as treatment for ER positive/HER2 negative advanced/metastatic breast cancer

The Center for Biosimilars

• Biosimilar Trastuzumab, Ogivri, and Its Reference in Combination With Pertuzumab Show Similar Activity

Breastcancer.org

• Experimental Tucatinib Improves Survival in Metastatic HER2-Positive Breast Cancer, May Be New Standard of Care
• Top News at 2019 SABCS – Heard in the Halls: Voices From the 2019 SABCS
• GRASP: Empowering Patients With Knowledge – Heard in the Halls: Voices From the 2019 SABCS
• Why Sexual Health Is Crucial for People With Metastatic Breast Cancer – Heard in the Halls: Voices From the 2019 SABCS
• Mets, Sex, and Side Effects – Heard in the Halls: Voices From the 2019 SABCS
• Beneath the Breast – Heard in the Halls: Voices From the 2019 SABCS

Healio

• Video Perspectives, SABCS
• Tucatinib regimen provides ‘unprecedented’ benefit in heavily pretreated HER2-positive breast cancer
• Ado-trastuzumab emtansine extends DFS in early-stage HER2-positive breast cancer
• Margetuximab extends survival in relapsed HER2-positive metastatic breast cancer
• Extended adjuvant letrozole improves DFS among certain postmenopausal women with breast cancer
• Adjuvant chemotherapy offers limited benefit for invasive lobular carcinoma

2018 Press 

Wednesday, December 5, 2018, Press Conference 1
7:15-7:45 a.m. CT

SABCS Co-director Carlos Arteaga, MD, director of the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern Medical Center, will moderate a press conference featuring the following research:

• Phase III KATHERINE Clinical Trial Crossed Early Reporting Boundary and Met its Primary Endpoint
• Adjuvant Capecitabine Did Not Significantly Improve Outcomes for Patients With Early-stage Triple-negative Breast Cancer